Page 20«..10..19202122..3040..»

Life ‘hanging by a thread’ for Italian cancer patients in coronavirus crisis – The Guardian

By daniellenierenberg

Since the coronavirus outbreak hit Italy, Francesca Masi has felt her life has been hanging by a thread. She was diagnosed with myelofibrosis, a rare bone marrow cancer, in 2016 and was due to have a transplant this month, but now fears it will be postponed as the country deals with the pandemic.

Access for thousands of cancer patients in need of chemotherapy, scans, transplants and surgery has become difficult, if not impossible, in Italys Covid-19 emergency.

Across the country, dozens of specialist cancer wards and hospitals have been transformed to treat coronavirus, while others have closed after medical staff and patients were infected. There are now fewer beds in intensive care units for cancer patients.

At the beginning of my diagnosis I underwent other treatments with success, but since my conditions worsened, transplant became my only option. So to be stuck in this situation make me living in a constant state of anxiety, says Masi, who lives and works in Pontedera, in the province of Pisa. She is 46 and the mother of a 10-year-old boy. I now run the risk of dying, which isnt fair, because my doctors had finally located two foreign donors whose marrow was 100% compatible with mine. International flight restrictions to halt the spread ofcoronavirus mean marrow from overseas donors risks not arriving in Italy.

Research led by Codice Viola, a charity that supports pancreatic cancer patients, and seen exclusively by the Guardian, found that of 500 mostly breast or pancreatic patients appointments for chemotherapy or radiotherapy were postponed for 24% (11% with no arranged date), while 64% of surgical procedures were postponed indefinitely. More than half have had follow-up appointments rescheduled.

Dozens of patients and doctors who spoke to the Guardian fear that the restrictive measures to contain the virus are limiting access to proper medical care for cancer patients, who also represent 17% of Italian coronavirus fatalities, according to a recent study.

Francesca Pesce, 54, a professional translator and member of Codice Viola, has been living with metastatic pancreatic cancer for almost three years. This week she will leave Rome for a follow-up in Milan, one of the cities worst affected by the virus.

At least I have this option, which others dont, she said. On the one hand, cancer patients are afraid of contracting the virus in hospitals, so they forgo their treatments; on the other, hospitals have been forced to cancel their appointments as many oncologists and anaesthetists have been moved to other wards to assist in the Covid-19 emergency.

Paolo Ascierto, an oncologist at Naples Pascale hospital now treating coronavirus patients, said converting cancer wards to Covid-19 units could be risky. I understand the state of emergency, but we mustnt forget that cancer patients require dedicated and specialised treatments. There are special conditions, like patients in follow-up, that can be managed safely using online consultations to monitor the patients progress.

But there are other conditions, such as metastatic patients, that must be prioritised, because a lack of constant attention can mean the difference between life and death.

In Ortona, Abruzzo, protests erupted following the announcement by local authorities that the only hospital in the region specialised in womens cancer treatments was to be entirely converted to treat Covid-19 patients.

Where cancer wards are functioning, certain diagnostic procedures, such as endescopies, may be limited, and a decrease in blood donations is limiting surgical options. At the moment, only urgent surgical procedures are being performed, says Pesce. And even urgent procedures are now stymied, because of a shortage of blood due to the coronavirus emergency.

The closure of air routes to and from Italy has also made it virtually impossible for thousands of cancer patients to access treatment in other European hospitals.

Alessandra Capone, 47, a dancer, feminist and human rights activist, has been living with breast cancer for 10 years. In 2015 it spread to her liver and lymph nodes and last year she began a series of treatments at University Hospital in Frankfurt with just 5% of her liver cancer-free. She is now facing enormous difficulties travelling to Germany.

I contacted the Ministry of Foreign Affairs and International Cooperation but the line is always busy and I couldnt speak to anybody. Then I contacted the Italian consulate in Frankfurt. They told me I need a number of certifications for travelling to another country, even for health reasons. Not to mention that in Germany very few hotels are accepting reservations, especially from Italians, during this emergency. Its very stressful.

For the first time, however, the Italian government last week authorised an air force flight to Turkey to secure haemopoietic stem cells from a donor for a two-year-old boy whose condition had worsened.

Travel is also limited within Italy, where patients from Sicily, Puglia and Calabria often undergo treatments and operations in richer Veneto and Lombardy, which are among the worst affected regions in the country for Covid-19.

Grazia De Michele, 39, a blogger and researcher in the history of medicine, lives in Foggia, in Puglia, and has been living with breast cancer since 2010. A few months ago, her mother was diagnosed with pancreatic cancer. My mother was supposed to have a CT scan in March to see if the chemo shes on is working, but the scan was postponed, she says. I was supposed to undergo an oophorectomy, and my operation was postponed as well.

You have to imagine what its like for cancer patients, says Capone. Many live in a constant state of anxiety, with the fear of dying. The situation caused by the coronavirus emergency has put them under enormous psychological and physical distress. You see, you can protect yourself from coronavirus by staying at home, but its not the same with cancer. Cancer doesnt follow the diktat of quarantines or decrees. It keeps going, in war and in peace.

See original here:
Life 'hanging by a thread' for Italian cancer patients in coronavirus crisis - The Guardian

To Read More: Life ‘hanging by a thread’ for Italian cancer patients in coronavirus crisis – The Guardian
categoriaBone Marrow Stem Cells commentoComments Off on Life ‘hanging by a thread’ for Italian cancer patients in coronavirus crisis – The Guardian | dataApril 8th, 2020
Read All

India Based Stem Cell Research Firm To Test Its Stem Cell Product For Acute Respiratory Disease Syndrome (ARDS) COVID-19 – IndianWeb2.com

By daniellenierenberg

Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG), announced today that it has partnered with Global Consortium of cell therapy companies seeking European Commission Funding to Fight Against Corona! (FAC!). Under this partnership, Stempeutics will export its stem cell product Stempeucel (subject to regulatory approvals) for treating critically ill COVID-19 patients with lung disease. First the product will be clinically tested and upon successful outcomes, it intends to export the product on a regular basis. In this connection it is signing up an alliance with Educell Ltd, Slovenia.

Currently, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. Mortality in COVID-19 infected patients with the inflammatory lung condition ARDS (Acute Respiratory Distress Syndrome)is reported to approach 50%, and is associated with older age, co-morbidities such as diabetes, cardiovascular disease, COPD (chronic obstructive pulmonary disease), higher disease severity, and elevated markers of inflammation. Current therapeutic interventions (with the exception of ventilators/respirators which are in very short supply) do not appear to be improving in-hospital survival. Hence, there is a large unmet need for a safe and effective treatment for COVID-19 infected patients, especially in severe cases. A promising new therapy for the ARDS, the terminal stage of COVID-19, using MSCs can quickly (2-4 days) reduce inflammation of the lung tissue, and allow patients to more quickly come off of the ventilatory support and hopefully fully recover with less significant lung damage.

Stempeucel is an allogeneic, off the shelf, pooled mesenchymal stromal cells having anti- inflammatory and immune-modulatory properties which prevents the over activation of the immune system. Stempeucel product exhibits a wide range of potent therapeutic properties. The product exhibits potent immunomodulatory and anti-inflammatory properties which could help in reducing the inflammation caused due to the cytokine storm elicited by the bodys immune cells in response to SARS-CoV-2 (COVID-19) related infection in the lungs. Also, the growth factor, Angiopoietin-1 (Ang-1) is effective in reducing alveolar epithelium permeability in the lung. Hence it is envisaged, Stempeucel will reduce the fatal symptoms of COVID 19 induced pneumonia and its progression to ARDS.

Commenting on this initiative, Dr. Miomir Knezevic, Leader of the Global Consortium and Founder of Educell said, We are happy to partner with Stempeutics since its product Stempeucel is already designated as an ATMP1 in Europe and also Stempeucel technology has been patented in many countries in Europe. Stempeutics manufacturing process is scalable and the product is affordable which are key to meet the demands of COVID-19 patients

Mr. BN Manohar, CEO of Stempeutics said, From the clinical data using Stempeucel in different clinical trials in other indications it may be postulated that Stempeucel has the potential capability for treating COVID-19 infection. Together with the safety profile observed from DCGI approved clinical trials involving more than 350 patients injected with Stempeucel by different routes of injection, this therapy may help in mitigating the lung tissue damaging effects of COVID-19 infection.

Dr. Stephen Minger, Scientific Advisor for the Global Consortium and ex Global Director of R&D, Cell Technologies GE Healthcare added The most severely affected CV-2 infected patients will often go on to develop ARDS which necessitates assisted ventilation to preserve breathing and lung function. Moreover, many ARDS patients will also experience an acute but severe life-threatening inflammatory response (cytokine storm) which can result in long-term damage to lung tissue and lung function. Treating ARDS patients with allogeneic expanded bone marrow derived MSCs could alleviate and ameliorate lung inflammation and compromised lung function and significantly reduce the time required for patients to be ventilated.

Dr. Raviraja N S, Sr. Director Business Development and Innovation, Stempeutics, said, Given the severe shortage of ventilators in the world, and the high mortality rate of patients who develop ARDS (approx. 50%), the clinical use of MSCs in COVID-19 ADRS patients could drastically impact on the healthcare burden currently occurring due to very large patient numbers, limited equipment and overworked medical personnel.

Mr. B N Manohar MD & CEO, Stempeutics Research

Manohar is the MD & CEO of Stempeutics Research a leading stem cell research and product development company in India. He earned his B.E. degree in Electronics & Communication from REC Trichy in 1977. Post that he did M.E. in Computer Science from College of Engineering, Guindy. Manohar has transformed Stempeutics a life science start-up from R&D to Commercialization stage with Global recognition. Stempeutics has developed an innovative drug called Stempeucel for addressing major unmet medical needs in India and Globally.

This drug developed by an Indian company has received many Global Recognitions. Fourteen countries including US & Japan has granted patent for the novelty and inventiveness of the drug. Europe has recognized this drug by granting Advanced Therapy Medicinal Product classification and Orphan Drug Designation. Recently it became the FIRST stem cell product to be approved by DCGI for conditional marketing for treating patients suffering from life threatening disease call Buergers Disease. Stempeutics has put India on the World map of Regenerative Medicine. Under Manohars leadership Stempeutics has been recognized as Indias hottest start-ups by Business Today in 2008 and Karnataka Government bestowed Emerging Company of the Year award in 2011 and 2013. In 2017 Manohar was awarded Biotechnologist of the Year award by Wockhardt Foundation, India. He raised US$ 10M in 2009 by establishing business alliance with major pharma company Cipla. Recently Stempeutics has tied up with Alkem Labs for Osteoarthritis indication. Prior to Joining Manipal Group, Manohar has had 12 years successful stints at Wipro GE Medical Systems. At GE Medical he has handled multiple senior assignments including Vice President Customer Service where he received GE Asia Service Award for highest revenue growth in 1998. Currently Manohar serves in the Boards of Stempeutics and MentisSoft.

Like this content? Sign up for our daily newsletter to get latest updates.

More:
India Based Stem Cell Research Firm To Test Its Stem Cell Product For Acute Respiratory Disease Syndrome (ARDS) COVID-19 - IndianWeb2.com

To Read More: India Based Stem Cell Research Firm To Test Its Stem Cell Product For Acute Respiratory Disease Syndrome (ARDS) COVID-19 – IndianWeb2.com
categoriaBone Marrow Stem Cells commentoComments Off on India Based Stem Cell Research Firm To Test Its Stem Cell Product For Acute Respiratory Disease Syndrome (ARDS) COVID-19 – IndianWeb2.com | dataApril 8th, 2020
Read All

Roma woman tells of her ‘life-changing’ MS treatment – Observer

By daniellenierenberg

THERES a 70 per cent chance youre going to get a mum without MS for the first time.

Those were the words Amanda Weyman-Jones told her daughter before they hopped on a plane, in a last ditch-attempt for Amanda to take her future back.

In January, Amanda and daughter Chloe travelled halfway across the globe to Moscow, Russia for a life changing and experimental treatment in hopes it would effectively stop her three decade battle with multiple sclerosis in its tracks.

The trip was made possible with the support from the Roma community who banded together to help Amanda raise $80,000 to pay for the treatment only available in the Russian capital.

And according to Amanda, she has already seen a massive improvement with her condition.

Im walking and I would say I have improved 70 per cent already, and its only expected to get better as time goes on, the 58-year-old mother of six said.

They say that the treatment gives you an 80 per cent (chance) of curing your MS and at the moment, I feel like Im in that 80 per cent Im feeling really good about my chances.

Amanda underwent an experimental procedure called Autologous haematopoietic stem cell transplant (AHSCT) treatment, which rebuilds the patients immune system.

Seven weeks on and Amanda says she feels like a new person, and has been walking around the football field everyday, which she states is a miracle as she couldnt even walk to the field before the treatment.

Ever since returning to Roma from Russia in February, all she has wanted to do is shout from the rooftops that others living with MS can also have their lives changed.

I heard about a man on a property in Blackall with MS and hes young so I want him to know he doesnt have to have this disease, you can get better, Mrs Weyman-Jones said.

This treatment gives you that infinity with people. Its life saving stuff.

Amandas brother Hayward and sister Diana were both diagnosed with MS too; Hayward died last year, and Diana is now in a wheelchair.

All too familiar with the devastating effects of MS, Amanda is determined to not become a burden on her loved ones.

Amanda who has Primary Progressive MS was given an Expanded Disability Status Scale (EDSS) score of 4.5 which notes a limited walking mobility to approximately 300m without aide prior to treatment. With no action taken, she would probably have continued to progress until she was wheelchair bound. The EDSS is scored zero to 10, with 10 marking a person has died from MS.

Now, with more improvements expected to continue in the next six to 12 months, Amanda is hopeful her quality of life will improve and once her immunity has built up, to continue working at the family-owned-and-run Overlander Motel.

I will be forever grateful to Dr Frederinco, the brilliant medical team in Russia, Roma, its local businesses and the wider community for blessing me with a new life, Amanda said.

Through the generosity and support by all, I have realised how lucky I am to be surrounded by such a caring community.

Amanda said she knew that while there is a long road ahead of her, every passing day she is more feeling more hopeful.

I was told that recovery can be like a rollercoaster, so I will accept the bad days and make sure I remember the good, she said.

My walking is slowly getting safer and less hazardous to myself . and to all other pedestrians. Every morning I wake up, knowing that every days a better day.

I am a new person, it is just a miracle.

Stats about MS

With MS Queensland aware of nearly 4000 people living with Multiple Sclerosis in Queensland and over 25,600 people in Australia living with the neurological condition.

Most people with MS in Australia experience their first symptoms between 20 and 40 years of age, with about three quarters of people living with MS, female.

MS is not considered a classic genetic disease in that there is not one single gene that causes the condition. Rather, there are more than 200 different known genetic factors which contribute to the risk of developing MS. It has been estimated that genes may account for around half of the risk for MS, and those with a family history of MS are at greater risk than the general population. Even so, the majority of people with a family member with MS will not develop the disease so genes on their own are not enough.

MS is caused by a complex interaction between a persons genetics and environment factors.

Autologous haematopoietic stem cell transplant (AHSCT) is an immunosuppressive chemotherapy treatment combined with reinfusion of blood stem cells to help rebuild the immune system.

AHSCT has been used for decades for the treatment of blood cancers. However in the past ten or so years a number of international observational studies of several hundred patients have been published with some patients being followed for five to eight years.

The treatment consisted of four days of stimulation before the stem cells were collected and then Amanda was pumped full of high dose chemotherapy.

Amanda then had a rest day, and on January 29, her harvested stem cells were returned to her MS ravaged body, signalling the rebirth of her immune system with no memory of MS.

After that she was given daily steroid infusions and was put into isolation for six nights before one final dose of chemotherapy.

Response from MS Queensland about the treatment

CEO of MS Queensland Zane Ali said MS Queensland and MS Research Australia are continuing to support Australian research in the use of AHSCT to treat multiple sclerosis.

Rigorous evidence for the efficacy and safety of AHSCT in relation to other MS therapies, and the most appropriate circumstances for its use, is required for Australian hospitals and clinicians to provide this intervention with equity and with greater confidence in the potential outcomes, he said.

Australian hospitals and doctors are likely to recommend AHSCT as a possible treatment only if the other approved MS therapies are not working for an individual with MS or cannot be used in an individual for other reasons.

Despite Amandas MRI revealing her Central Nervous System was so progressed (with 35 lesions or more on the spine), she met the criteria for the treatment because of her mobility.

You have to be at a very healthy besides having MS, patients are tested from head to toe when they first arrive in hospital to ensure that they dont have any cancers or illnesses that could effect the viability of the treatment, said daughter Chloe.

The doctor was surprised after he saw how mobile mum still was considering the damage that he saw in her brain.

People arent accepted all of the time, some are told before they go and some are only told after all of the testing is completed in Moscow, then they are then sent home. International studies also suggest AHSCT does not halt or reverse progressive forms of the disease, and is therefore unlikely that

AHSCT would be recommended as a treatment for patients with secondary progressive or primary progressive MS.

Currently the treatment is provided in Australia through two observational clinical trials, at St Vincents, Sydney and Austin Health, Melbourne and by a small number of other centres on a case-by-case basis.

These centres have strict eligibility requirements that have been set by the hospital ethics committees and may only apply to limited numbers of patients with MS, Mr Ali said.

It is for this reason patients need to be referred to these centres by a neurologist, who can provide a detailed clinical history and MRI findings, Mr Ali said.

Mr Ali said that data from the large European Bone Marrow Transplant Registry suggests that in approximately 55 per cent of people with MS, treated with a range of different chemotherapy regimens, at three years of follow-up, inflammatory disease is halted with no evidence during the follow-up period of relapses, active brain lesions or disability progression.

After five years approximately 45 per cent of people remain progression free.

This case series included patients with both relapsing remitting and progressive disease, he said.

Other smaller studies have shown similar results, with remission of disease seen in these studies in at least 63 per cent of patients followed for a minimum of three years.

Most studies also show that the risk of disease activity returning gradually increases over longer periods of follow-up.

Mr Ali said in some but not all, of the people with MS who respond to AHSCT, some reversal of disability has been noted in some studies.

Other patients may continue to experience disease activity and disability progression (worsening) despite treatment with AHSCT, he said.

In people with progressive forms of MS or relapsing remitting MS of longer duration, the benefits of the procedure have been much less clear and accumulation of disability usually continues.

Amanda said they chose Moscow for the treatment because despite other countries offering the experimental procedure, after thorough research they found Russia had the highest rate of treatment success.

They accept advanced progressive MS where most of the other clinics offering it only treat relapsing remitting MS, she said.

I was still on my feet (only just) but people went over in wheelchairs, walkers, walking sticks and many were older than me.

For Chloe, who is training to become a nurse and who spent every spare moment researching AHSCT treatment said while they mostly compared the options available in Mexico and Russia, Russia stood out to them because it was cheaper and they had more experience.

One of the major influencing factors was that in Mexico patients stayed in a complex with they carer and in Russia patients stayed in a hospital, so we felt more reassured knowing that mum would have 24 hour care provided to her at the touch of a buzzer, she said.

Great lengths of a loving daughter

Although Amanda has lived with MS for 34 years, she feels like she is one of the lucky ones.

None of this would have been possible without Chloe. Her drive and determination surprises me every day, she said.

Researching, booking, fundraising and organising the whole trip, proves to me that I am the luckiest mum on earth.

Chloe was the driving force behind the push for treatment and the GoFundMe campaign which raised over half the $80,000 goal was with her mum every step of the journey.

I have found spending a month in Russia very interesting, the first couple of weeks for easy, but after that I just wanted to come home to Australia, the 19-year-old said.

Every day I would go and visit Mum in the morning and stay there with her until dark and then head on back to the hotel, I basically just did that every day.

I made some great friends with some other patients carers and so often we would catch up at the end of the day to recuperate and support each other.

Although the month spent away from her loved ones began to take its toll, Chloe has high hopes for the future.

It was very draining being over there, I felt like I wasnt doing much but I was just always so tired, she said.

Its amazing to see how quickly mum is healing after the treatment, but it will take some time to see what the true outcome for her is going to be.

In the end, we dont know what the future holds for mum and her MS, we are just thinking positively and hope that we see improvements over the next 12 months.

We feel very lucky that we had the opportunity to go over and are now advocating for other people to have the treatment as well.

Chloe and Amanda Weyman-Jones sightseeing in Moscow before the treatment began.

During the treatment.

Amanda Weyman-Jones with Greta and Theresa who were also going through the treatment.

Read the original post:
Roma woman tells of her 'life-changing' MS treatment - Observer

To Read More: Roma woman tells of her ‘life-changing’ MS treatment – Observer
categoriaBone Marrow Stem Cells commentoComments Off on Roma woman tells of her ‘life-changing’ MS treatment – Observer | dataApril 8th, 2020
Read All

Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of…

By daniellenierenberg

CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has contributed to two new peer-reviewed papers under the U.S. Food and Drug Administrations (FDA) CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative. The papers, in Nature Scientific Reports1 and Toxicology and Applied Pharmacology2, focus on application of improved cardiac safety testing protocols and recommendations for best practice for the drug discovery industry.

The CiPA Initiative (www.cipaproject.org), which began in July 2013 following a workshop at the US FDA, has the objective to revise and enhance the regulatory framework assessing cardiac safety of new chemical entities. Under current guidelines, new therapeutics undergo initial assessment of proarrhythmic risk by measuring activity against the hERG cardiac ion channel, before progressing to studies in preclinical animal models and ultimately, a Thorough QT interval study in the clinic. The CiPA initiative aims to extend the use of advances in early electrophysiology-based cardiac ion channel screening, in silico predictive modelling, and human induced pluripotent stem cell derived cardiomyocytes to improve the accuracy and reduce the cost of predicting the cardiac liability of new drug candidates. Metrions research forms part of the first stage of the proposed harmonisation work, to provide clarity on how to standardise cardiac ion channel assays to ensure they deliver consistent data for in silico models of clinical cardiac arrythmia risk.

The first paper1, published in Nature Scientific Reports on 27th March 2020 by an international group of authors drawn from 20 different commercial and academic laboratories, including Metrion Biosciences, was coordinated by the Health and Environmental Sciences Institute (HESI). It reviews data from a multi-year, multi-site collaboration across industry, academia and the FDA regulatory agency to optimize experimental protocols and reduce experimental variability and bias. The goal of the study was to guide the development of best practices for the use of automated patch clamp technologies in early cardiac safety screening. High quality in vitro cardiac ion channel data is required for accurate and reliable characterisation of the risk of delayed repolarisation and proarrhythmia in the human heart and to guide subsequent clinical studies and regulatory submissions.

The second paper2, to be published formally in Toxicology and Applied Pharmacology paper on 1st May 2020 but currently available online, uses automated patch clamp data from the CiPA consortium to address the lack of statistical quantification of variability, which hinders the use of primary hERG potency data to predict cardiac arrhythmia. The consortium establishes a more systematic approach to estimate hERG block potency and safety margins.

Dr Marc Rogers, CSO, Metrion Biosciences, said: The Metrion team has been a participant in the international CiPA Initiative since inception and we are now pleased to be able to announce the publication of our data from this global collaborative scientific effort. We believe these projects will make a significant contribution to the eventual revision of cardiac safety testing guidelines by the FDA and other international regulatory agencies. They also contribute to deepening our knowledge of the underlying causes of proarrhythmia, which will help prevent early attrition of potentially promising drugs.

Contributing organisations to the Nature Scientific Reports CiPA study include: Charles River Laboratories; Bayer AG; Sophion Bioscience A/S; Nanion Technologies; GlaxoSmithKline PLC; Pfizer; Sanofi R&D; Astra Zeneca; BSYS GmbH; Bristol-Myers Squibb Company; Eurofins Discovery; Merck; Metrion Biosciences Ltd.; Natural and Medical Science Institute at the University of Tbingen; Northwestern Feinberg School of Medicine, Chicago; Roche Innovation Center Basel; Novoheart; Health and Environmental Sciences Institute, Washington, DC; AbbVie.

Contributing organisations to the Toxicology and Applied Pharmacology hERG study include: Center for Drug Evaluation and Research, Food and Drug Administration; Eli Lilly and Company; AstraZeneca; CiPA LAB; NMI-TT GmbH; Sophion Bioscience A/S; B'SYS GmbH; The Ion Channel Company; F. Hoffmann-La Roche AG; Eurofins Discovery; Bristol-Myers Squibb; Merck & Co., Inc; Metrion Biosciences Ltd.; Nanion Technologies; Charles River Laboratories; Bayer AG; University of Nottingham; Universit de Lille.

For more information on Metrions fully integrated Cardiac Safety Screening / CiPA Screening service, please visit: https://www.metrionbiosciences.com/services/cardiac-safety-screening/

Merion Biosciences comprehensive cardiac safety testing White Paper The changing landscape of cardiac safety will also be available on the Companys website from 13th April 2020.

Link:
Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of...

To Read More: Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of…
categoriaCardiac Stem Cells commentoComments Off on Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of… | dataApril 8th, 2020
Read All

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market [News 2020] Intelligence and Future Prospects 2025 – Fashion Trends News

By daniellenierenberg

Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report covers the existing situation and the development predictions of the industry for 2020. This report has prepared mainly on the basis of a common market assessment with input from industry experts. This estimated report consists of all have observed element about marketplace evaluation, increase Demand and forecast analysis in all over the world. This record gives a few edged examine and solution within the complicated international of polymer-based totally thermal interface materials market.

Report Covers Following Key Players:-

U.S. STEM CELL, INC., Brainstorm Cell Therapeutics, Cytori, Dendreon Corporation, Fibrocell, Lion Biotechnologies, Caladrius Biosciences, Opexa Therapeutics, Orgenesis, Regenexx, Genzyme, Antria, Regeneus, Mesoblast, Pluristem Therapeutics Inc, Tigenix, Med cell Europe, Holostem, Miltenyi Biotec.

For Better Understanding Go With This Free Sample Report Enabled With Respective Tables and Figures @ https://www.eonmarketresearch.com/sample/55837

>> [ Conjointly enclosed free report contains a quick introduction to the abstract, table of contents, list of tables and figures, competitive landscape and geographic segmentation, innovation and future developments supported the methodology of investigation.] <<

The market report defines the growth of the industry by upstream and downstream, by the industry as a whole and by production, by key companies as well as by product segment and application, and so on, and makes a scientific forecast for the technology industry on the basis of an analysis.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report quantifies opportunities and Challenges to prioritize with the revenue. The report describes each aspect in depth, such as Business Strategies, Market Trends, Regional Growth, Quality Matrix. This vital data about Autologous Stem Cell and Non-Stem Cell Based Therapies industry will help to improve market growth in terms of manufacturing capacity, Sales during the Forecast period of 2020.

Market Segment by Regions:-

USAEuropeJapanChinaIndiaSoutheast Asia

Scope of the Report:

This study focuses on the global market for Autologous Stem Cell and Non-Stem Cell Based Therapies especially in Europe, North America and Asia-Pacific, the Middle East and Africa, and South America. The report defines the market based on regions, size, manufacturers and applications.

Click Here For Inquiry and Ask For Discount Here- https://www.eonmarketresearch.com/enquiry/55837

Market Segment On The Basis Of Product Type Includes:-

Embryonic Stem CellResident Cardiac Stem CellsAdult Bone MarrowDerived Stem CellsUmbilical Cord Blood Stem Cells

Applications Mentioned In This Report:-

Neurodegenerative DisordersAutoimmune DiseasesCancer and TumorsCardiovascular Diseases

The report then estimates 2020 market development trends of Autologous Stem Cell and Non-Stem Cell Based Therapies market. Outline of upstream raw materials, downstream trade and prevailing market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Autologous Stem Cell and Non-Stem Cell Based Therapies market before evaluating its feasibility.

This report presents an extensive analysis of the current Autologous Stem Cell and Non-Stem Cell Based Therapies trends and emerging estimations & dynamics of the global Autologous Stem Cell and Non-Stem Cell Based Therapies industry. Likewise, explains the comprehensive analysis of factors that drive and restrict the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies market. Further covers a detailed analysis of the Autologous Stem Cell and Non-Stem Cell Based Therapies industry based on type and application help in understanding the Autologous Stem Cell and Non-Stem Cell Based Therapies trending products across geographies. Then highlights the potency of buyers and suppliers to understand the Autologous Stem Cell and Non-Stem Cell Based Therapies market potency. Finally, an extensive analysis of the Autologous Stem Cell and Non-Stem Cell Based Therapies market is conducted by key product positioning and monitoring of top players within the Autologous Stem Cell and Non-Stem Cell Based Therapies market framework.

Table of Contents:

1 Industry Overview of Autologous Stem Cell and Non-Stem Cell Based Therapies.2 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Competition Analysis by Players.3 Company (Top Players) Profiles.4 Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Size by Type and Application (2020-2025).5 United States Autologous Stem Cell and Non-Stem Cell Based Therapies Development Status and Outlook.6 EU Ophthalmology DiagnosticsDevelopment Status and Outlook.7 Japan Autologous Stem Cell and Non-Stem Cell Based Therapies Development Status and Outlook.8 China Autologous Stem Cell and Non-Stem Cell Based Therapies Development Status and Outlook.9 India Autologous Stem Cell and Non-Stem Cell Based Therapies Development Status and Outlook.10 Southeast Asia Autologous Stem Cell and Non-Stem Cell Based Therapies Development Status and Outlook.11 Market Forecast by Regions, Type, and Application (2020-2025).12 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Dynamics.13 Market Effect Factors Analysis.14 Research Finding/Conclusion.15 Appendix.

**Thanks for reading this article; you can also get individual chapter wise section or region wise report version like United States, Europe, Middle East and Africa or Asia-Pacific.**

About Us:

Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email: sales@eonmarketresearch.com

Originally posted here:
Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market [News 2020] Intelligence and Future Prospects 2025 - Fashion Trends News

To Read More: Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market [News 2020] Intelligence and Future Prospects 2025 – Fashion Trends News
categoriaCardiac Stem Cells commentoComments Off on Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market [News 2020] Intelligence and Future Prospects 2025 – Fashion Trends News | dataApril 8th, 2020
Read All

Don’t Be Flaky: Try One of These Scalp Treatments From Sephora and Get Your Scalp Right – POPSUGAR

By daniellenierenberg

If you notice flakes in your hair or it's simply looking drab, chances are there's something making its home on your head that you definitely don't want there. Depending on your own pH levels, it could be the oil from clogged follicles creating dandruff, but even if you consider your scalp on the normal-to-dry side, product buildup can still linger on the scalp long after you've showered with shampoo and conditioner.

If you'd like to say a final farewell to product buildup, dead skin cells, and excess sebum, using a purifying scalp scrub once a week can exfoliate away dirt and flakes and leave your hair feeling cleaner than you've ever imagined. Beyond scrubs, other treatments like serums and oils can also help fortify follicles so hair grows back in healthier and stronger, plus treat the protective cuticle layer that locks in moisture and keeps hair looking shiny, too.

Check out the best hair-care products at Sephora that tackle everything from itchiness to dullness ahead, and give your scalp the special treat it's not-so-secretly seeking.

Follow this link:
Don't Be Flaky: Try One of These Scalp Treatments From Sephora and Get Your Scalp Right - POPSUGAR

To Read More: Don’t Be Flaky: Try One of These Scalp Treatments From Sephora and Get Your Scalp Right – POPSUGAR
categoriaSkin Stem Cells commentoComments Off on Don’t Be Flaky: Try One of These Scalp Treatments From Sephora and Get Your Scalp Right – POPSUGAR | dataApril 8th, 2020
Read All

Meet the sci-fi startup building computer chips with real biological neurons – Digital Trends

By daniellenierenberg

Theres a great deal of innovation embedded in todays cutting-edge computer chips, but not much of it is as out-of-the-box as the thinking thats driving Australian startup Cortical Labs. The company, like so many startups with artificial intelligence in mind, is building computer chips that borrow their neural network inspiration from the biological brain. The difference? Cortical is using actual biological neurons, taken from mice and humans, to make their chips.

Were building the first hybrid computer chip which entails implanting biological neurons on silicon chips, Hon Weng Chong, CEO and co-founder of Cortical Labs, told Digital Trends.

This is done by first extracting neurons in two different ways, either from a mouse embryo or by transforming human skin cells back into stem cells and inducing those to grow into human neurons.

We then grow those neurons in our laboratory on high density CMOS-based multi-electrode devices that contain 22,000 electrodes on tiny surfaces no larger than 7mm squared, Chong continued. These neurons form neural networks which then start to spontaneously fire electrical signals, after a two-week incubation period, that is picked up by our multi-electrode device. The multi-electrode device is also able to provide electrical stimulation.

The researchers arent the first to develop neural networks based on real neurons. Recently, scientists in the U.K., Switzerland, Germany, and Italy fired up a working neural network that allowed biological and silicon-based artificial brain cells to communicate with one another over an internet connection.A California startup called Koniku, meanwhile, is building silicon chips, created using mouse neurons, which are able to sense certain chemicals.

For now, research like Cortical Labs is still in a relatively early proof-of-concept stage. According to a recent article in Fortune, Cortical Labs current approach has less processing power than a dragonfly brain. That means that, for now, its pursuing humbler ambitions than its eventual goal.

While were still in the process of building the hybrid computer chip, right now were focused on shaping our neurons behavior to play a game of [Ataris] Pong, Chong said. Thats our next big milestone, which will provide a proof-of-concept similar to DeepMinds demonstration [in 2013] of its A.I. playing Breakout.

Commercialization is still a number of years away, Chong continued. But hes convinced it could be a game-changer. When we eventually take our final product to market we believe it will have a wide array of applications across robotics, cloud computing, and computer brain interfaces, he said. This does not include industries that we might not have thought about yet because of the novelty of such a computation paradigm.

Read the rest here:
Meet the sci-fi startup building computer chips with real biological neurons - Digital Trends

To Read More: Meet the sci-fi startup building computer chips with real biological neurons – Digital Trends
categoriaSkin Stem Cells commentoComments Off on Meet the sci-fi startup building computer chips with real biological neurons – Digital Trends | dataApril 8th, 2020
Read All

Lockdown skin: Why is my skin worse even though I’m not wearing any makeup? – Express

By daniellenierenberg

The coronavirus crisis is affecting every aspect of our lives, including the condition of our skin. Have you noticed that your skin is particularly spotty, irritated and angry lately? That's another thing you can blame on COVID-19.

Express.co.ukspoke to Dr. Luca Russo, Dermatologist at Urban Retreat, to find out why.Dr. Russo says there are several reasons for your unexpected breakouts.He said: "There might be several reasons for noticing a tendency to break out during this national emergency."It's probably to do with what's going on inside, and what you're putting in your body, says Dr. Russo.

READ MORE- Coronavirus symptoms: Man reveals skin-related warning sign

Are you up all night worrying about the virus?Dr. Russo says: "The most likely cause of your breakout is stress."During such uncertain and stressful times, our system copes with increased production of Cortisol."Cortisol is an androgen hormone that is released when we are facing unusual challenges and prepare us to "fight'."However, it will also increase the sugar level in the bloodstream and production of sebum that might be a cause of the breakout."

In order to prevent breakouts that stem from high levels of stress, you'll need to calm yourself down.Dr Russo recommends doing activities that allow you to relax and unwind, such as yoga.He also suggests exercising regularly, so it's time to start making use of that daily government-approved walk, cycle, or run.

If you hate exercising, don't worry, the antidote to high cortisol levels doesn't have to be physical.Laughing, a solid night of sleep, or practising your favourite hobby are all effective options.

Having a soak in the bath and doing a face-mask may help you feel more in control of your skin.

This relief may cause a decrease in oil production and pimples.

DON'T MISS...How to help your brain through the coronavirus crisis stress [EXPLAINER]Coronavirus: How to look after your mental health during lockdown [EXPLAINER]Lockdown exercise: The eight exercises you can do at home [INFORMER]

Can you honestly say you have been eating well throughout the lockdown?Most people have stocked up on sugary treats and salty snacks in order to cheer themselves up in the face of COVID-19.And what about the good-old "support local businesses" excuse you use every time you order a greasy takeaway?Dr Russo says: "During isolation food becomes one of the few focal points of the day with more consumption of comfort food."Just like any other organ in your body, a poor diet affects your skin negatively.The body breaks down our food into tiny particles of proteins, fats, and carbs, and circulates it to the organs that need them.These nutrients make their way to your skin too, impacting its condition.It makes sense that inflammatory foods, such as sweets, some dairy, processed meat, and refined carbohydrates, will cause a flare-up in your complexion.

Dr. Russo says: "To improve your skin, you must eat well."Eat foods that are packed with vitamins and proteins and snack on fruit and veg."Drinking lots of water will replace the moisture that is lost through sweat and other processes, keeping your skin hydrated.If you fill up on foods rich in healthy oils and omega-3 fatty acids, you will improve the collagen production in your skin.This makes your skin smoother, suppler, and will help you in the longterm by preventing premature ageing.These oils and fats are found in fish, nuts, olive oil, and many more commonly found items.

During the lockdown, we're stuck inside all day and often don't get a chance to let our skin feel the sun.Dr. Russo says: "At the moment, skin isn't being exposed to natural light much at all."When your skin is exposed to natural light, the production of Vitamin D is increased."Endorphins are also produced, and this boosts your immune system and well-being."Make sure you get some fresh air every day, in order to reap these benefits of the sun.The sun is a great natural resource to improve your skin, but make sure you protect yourself with sun protection before you go out.You should wear an SPF of at least 30 on your face whenever you leave the house or are in front of a window for a prolonged amount of time.

Most people are shunning makeup in favour of the natural look since no one other than our household is going to see our faces.This means you may be tempted to skip your cleansing routine and go straight to bed once the day is over.

If you normally get facials and now can't, this may also be why you are breaking out or seeing changes.Dr. Russo explains: "You have probably been unable to receive professional treatments over this time, and this will contribute towards your breakouts."Dr. Russo recommends continuing with your normal skincare routine.He says: "Carry on as normal, but add an exfoliating cleanser to your routine."Exfoliating cleansers make your skincare routine shorter, by combining exfoliating and cleansing in one step.They remove dead skin cells and any build-up of dirt and oil in one go.There are hundreds of physical exfoliating cleansers on the market, as well as chemical exfoliating cleansers, so take your pick!

While surgical masks are thought to protect us against coronavirus, they're not great for our skin, said Dr. Russo.Wearing a mask over your face for many hours is damaging to your skin, especially when it's hot outside.The mask offers the perfect spot for bacteria and germs to harbour.Try double cleansing on the lower half of your face if you've worn a surgical mask for a prolonged period of time.

More:
Lockdown skin: Why is my skin worse even though I'm not wearing any makeup? - Express

To Read More: Lockdown skin: Why is my skin worse even though I’m not wearing any makeup? – Express
categoriaSkin Stem Cells commentoComments Off on Lockdown skin: Why is my skin worse even though I’m not wearing any makeup? – Express | dataApril 8th, 2020
Read All

Meet the sci-fi startup building computer chips with real biological neurons – Yahoo Tech

By daniellenierenberg

Theres a great deal of innovation embedded in todays cutting-edge computer chips, but not much of it is as out-of-the-box as the thinking thats driving Australian startup Cortical Labs. The company, like so many startups with artificial intelligence in mind, is building computer chips that borrow their neural network inspiration from the biological brain. The difference? Cortical is using actual biological neurons, taken from mice and humans, to make their chips.

Were building the first hybrid computer chip which entails implanting biological neurons on silicon chips, Hon Weng Chong, CEO and co-founder of Cortical Labs, told Digital Trends.

This is done by first extracting neurons in two different ways, either from a mouse embryo or by transforming human skin cells back into stem cells and inducing those to grow into human neurons.

We then grow those neurons in our laboratory on high density CMOS-based multi-electrode devices that contain 22,000 electrodes on tiny surfaces no larger than 7mm squared, Chong continued. These neurons form neural networks which then start to spontaneously fire electrical signals, after a two-week incubation period, that is picked up by our multi-electrode device. The multi-electrode device is also able to provide electrical stimulation.

The researchers arent the first to develop neural networks based on real neurons. Recently, scientists in the U.K., Switzerland, Germany, and Italy fired up a working neural network that allowed biological and silicon-based artificial brain cells to communicate with one another over an internet connection.A California startup called Koniku, meanwhile, is building silicon chips, created using mouse neurons, which are able to sense certain chemicals.

For now, research like Cortical Labs is still in a relatively early proof-of-concept stage. According to a recent article in Fortune, Cortical Labs current approach has less processing power than a dragonfly brain. That means that, for now, its pursuing humbler ambitions than its eventual goal.

While were still in the process of building the hybrid computer chip, right now were focused on shaping our neurons behavior to play a game of [Ataris] Pong, Chong said. Thats our next big milestone, which will provide a proof-of-concept similar to DeepMinds demonstration [in 2013] of its A.I. playing Breakout.

Commercialization is still a number of years away, Chong continued. But hes convinced it could be a game-changer. When we eventually take our final product to market we believe it will have a wide array of applications across robotics, cloud computing, and computer brain interfaces, he said. This does not include industries that we might not have thought about yet because of the novelty of such a computation paradigm.

Visit link:
Meet the sci-fi startup building computer chips with real biological neurons - Yahoo Tech

To Read More: Meet the sci-fi startup building computer chips with real biological neurons – Yahoo Tech
categoriaSkin Stem Cells commentoComments Off on Meet the sci-fi startup building computer chips with real biological neurons – Yahoo Tech | dataApril 6th, 2020
Read All

The rise of ‘rich woman face’: how to halt the ageing process (for a certain price) – Telegraph.co.uk

By daniellenierenberg

'Let me tell you about the very rich,' wrote F Scott Fitzgerald. 'They are different from you and me.' Above all, in the lengths they will go to acquire, and preserve, perfect skin.

Sheikha Moza bint Nasser, the consort of the former Emir of Qatar, may well be the richest person I've ever met. She certainly has skin like no one else on the planet. She's 61 but looks about 40, with a face that seems to have no visible pores, perhaps because it's sculpted out of alabaster.

Admittedly, she is carefully made-up on a regular basis, so she would have been unlikely to want to attend a recent dinner party of Gwyneth Paltrow's in Beverly Hills, at which guests were banned from wearing any cosmetics at all. Kate Hudson and Demi Moore were among those who gamely took the challenge, the idea of which was to allow the assembled LA A-listers to show off their natural glow.

But they don't, of course, rely wholly on nature for their radiance. Moore's evening beauty routine (pared back to the minimum because, she says, "I like to keep it simple") includes eight separate products, with a total cost of 743.50, from a cleansing elixir to a 355 replenishing facial oil and a rose-quartz facial massager in the shape of a butterfly.

No wonder that, far from being petrified at the thought of the make-up-free dinner, she felt 'full of joy', according to her Instagram posts. Her face wasn't coated in foundation, but it was insulated by a thick layer of cash.

With skincare that promises actually to reverse the visible signs of ageing, beauty brands feel entitled to charge impressive sums. La Prairie has one serum, its Platinum Night Elixir, that sells for over 1,000 for 20ml. It costs about 10 more per gram than solid gold. Imagine if your cat knocked that one off the dressing table.

On the other hand, the scientist who developed it says the peptides and amino acids contained in a single daily drop will leave your skin visibly younger-looking and fresher in two weeks. Users say it feels like wrapping your face in cashmere.

La Prairie Platinum Rare Cellular Night Elixir 20ml, 1,018, Harvey Nichols

I rely on Dr Phillip Levy, a Swiss dermatologist and wound-healing specialist based in Geneva, whose moisturisers and serums are proven to revitalise dermal stem cells to kick-start your skin's own production of collagen. Another doctor - German-born Michael Prager, who operates from a clinic in Wimpole Street - emphasises the rejuvenating effects of combating pollution with an antioxidant cream that fights off free radicals.

Neither of these medical-grade ranges comes cheap, but though Dr Prager's day oil contains pure gold, at 225 for 30ml (drmichaelprager.com), it's not actually as expensive as buying the precious metal itself.

If you're going down the Sheikha Moza route to moneyed perfection with a lavish use of make-up, Gucci Westman is a name to conjure with. This make-up artist, who has worked with Natalie Portman and Nicole Kidman, has her own range, Westman Atelier.

Lip suede in Les Rouges, 75, Westman Atelier (net-a-porter.com)

Yes, the colours are lush but, even better, the brand is 'clean' - beauty-speak for vegan, against animal-testing, paraben-free and so on. Plus, the products moisturise, plump up collagen and soothe as you apply them. Even the mascara conditions your lashes. So what if it costs 58?

Equally impressive is Shiseido's luxury line, Cl de Peau, which does a foundation that's 250 for 27ml, in 13 shades. Again, it's a beauty treatment with SPF and moisturiser as much as a make-up product, and it's what I'll put on if I want anyone to tell me I look glowing.

But, of course, more precious than any cream or blush stick is a little personal attention. Dr Costas Papageorgiou operates out of Harrods and has fairly expensive-looking skin himself. He makes use of a battery of lasers, Botox, fillers and ultrasound, but the key to his success is the consultation that starts off the process.

The Foundation,250, Cl de Peau Beaut (harrods.com)

Seeing your own face in unforgiving 3D on a computer may be a shock, but it certainly helps pinpoint the areas you'd like him to focus on. He's very hot on correcting facial symmetry, which starts out pretty good in babies, but with time and use, the muscles on the face become less symmetrical as bits start to droop or wrinkle. Generally, the more lopsided you are, the more antique you look, and he can address that with filler, Botox and even thread lifts.

But I'm not one for the injectables. It's his Hybrid Energy Lift - a combination of ultrasound, infrared, light and laser - that I really rate (from 6,000 for 120 minutes, facialplasticslondon.com). It, too, stimulates collagen production, but it also gets rid of visible veins and redness, and even reduces big pores. I have had to change the tone of my foundation for a paler one since he did for my (mild) rosacea.

Radical3 Reboot Pro Peel, 89, Dr Levy (editorslist.co.uk)

The key, says Dr Papageorgiou, is to delay and reverse the "ageing cascade". This slow car crash of fine lines around the eyes, sun damage and heavy jowls is all thanks, he says, to "fat atrophy and bone resorption".

But subtlety is all - "A great result is one that shows no signs of intervention"- and nothing, he warns, can really be achieved unless you have a healthy diet, exercise and take vitamins.

Debbie Thomas, at her D.Thomas clinic in London, has a similarly personalised approach. You don't book in for a single treatment, you book for an hour of her expert time, and she'll use a cocktail of lasers, micro-needling and products depending on what you need (475 for a DNA Laser Complete 2 session, dthomas.com).

"I'm afraid,"she says, "traditional facials are not going to transform your skin for more than a few days. You need to upgrade to more advanced treatments if you want long-term results. And those will be more costly."And who can say it's not worth the money?

Sign up for theTelegraphLuxury newsletterfor your weekly dose of exquisite taste and expert opinion.

Read this article:
The rise of 'rich woman face': how to halt the ageing process (for a certain price) - Telegraph.co.uk

To Read More: The rise of ‘rich woman face’: how to halt the ageing process (for a certain price) – Telegraph.co.uk
categoriaSkin Stem Cells commentoComments Off on The rise of ‘rich woman face’: how to halt the ageing process (for a certain price) – Telegraph.co.uk | dataApril 6th, 2020
Read All

Meet Betty Hay, the scientist who saw how cells grow and limbs regenerate – Massive Science

By daniellenierenberg

Limbs regenerate, embryos grow, and cancers invade.

In each of these processes, cells change dramatically. Betty Hay studied fascinating biological phenomena, relentlessly asking questions with her students and colleagues to understand how cellsbehaved. By the end of her life, she had made enormous research contributions in developmental biology, on top ofcommitting herself to mentoring the next generation of scientists and advocating for more representation of women in science.

She made significant contributions towards understanding cell and developmental biology

Betty Hay began as an undergraduate at Smith College in 1944. She lovedher first biology course and started working for Meryl Rose, a professor at Smith who studied limb regeneration in frogs. I was self-motivated and very attracted to science, she saidin an interview in 2004, Meryl at that time was working on regeneration and by the end of my first year at Smith I was also studying regeneration.

Hay regarded Rose as a significant scientific mentor in her life and followed his advice to apply for medical school instead of graduate school. She ended up attending Johns Hopkins School of Medicine for her medical degree while continuing her research on limb regeneration over the summers with Rose at Woods Holes Marine Biological Laboratory. She stayed at Johns Hopkins after to teach Anatomy and became an Assistant Professor in 1956.

The year after, she moved her studiesto Cornell Universitys Medical College as an Assistant Professor to learn how to use the powerful microscopes located there. Her goal was to use transmission electron microscopy (TEM), a method of taking high-resolution images, toseehow salamanders could regenerate an amputated limb. Nothing couldve kept me from going into TEM, she said later.

With her student, Don Fischman, they concluded that upon amputation, cells with specialized roles,known as differentiated cells and thought to be unchangeable, were able to de-differentiate and become unspecialized stem cells again. These cells without an assigned role could then have the freedom to adopt whatever new roles they required to regenerate a perfectly new limb.

Already making leaps in figuring out an explanation for the process of limb regeneration, Hay turned her attention from salamanders to bird eyes when she moved to Harvard University. She studied the outermost layer of cells on the cornea, known as the cornea epithelium. With the help of a postdoctoral scholar in her lab, Jib Dobson, and a faculty colleague, Jean-Paul Revel, they isolated, grew, and took pictures of cornea epithelium cells and demonstrated the epithelial cells could produce collagen.

Collagen is the main type of protein that weaves together to form the extracellular matrix, a connective tissue (the matrix) found outside of cells (extracellular). The collagen in the extracellular matrix provide structure, acting as a foundation for connective tissues and organs such as skin, tendons, and ligaments. Other scientists in the field were skeptical of the conclusion. They thought that one dedicated cell produced collagen, and nothing else.They dismissed the idea that cells in the cornea could somehow do the same. Despite their doubt, Hay, along with postdoctoral scholar Steve Meier, continued their studies. In 1974, they further showed that not only could epithelial cells produce collagen and extracellular matrix in different organ systems, but that the matrix could also tell other cells what type of cell to become.

She was a committed educator and mentor

Kathy Svoboda and Marion Gordon, two colleagues of hers, wrote about Betty Hay and described her not only as a superb cell and developmental biologist, but also as an educator and beloved mentor.

Limb regeneration in salamanders

Russell et al BMC Biology 2017

She was dedicated to teaching and influenced the careers of many junior and early-career scientists. In addition to working with and training her students to produce successful research and results, others mentioned how she would take the time to introduce students in her department to more established and prominent scientists in the field of cell biology. These actions reflected her belief that every student was worthy of being heard and introduced.

She held influential positions and advocated for more representation of women in science

At the time of her graduation from Johns Hopkins in 1952, she was one of only four women in her graduating class of 74 people. Afterwards, she experienced frequent moves for her career, going from Baltimore, to New York, to Boston. Despite how difficult it felt moving alone and leaving her personal relationships behind every time, she felt it was necessary for her career. In her mind, she strongly believed her research always came first, fueled by her intense desire to find answers, using the scientific approach.

She went on to serve as president for multiple professional societies, such as the American Association of Anatomists, the American Society for Cell Biology, and the Society for Developmental Biology, demonstrating her commitment to leadership and service. In two of these societies, she was the first woman to ever hold the position.

In 1975, she became the first female chair of what is now the Department of Cell Biology at Harvard University and held that position for 18 years. Even with these impressive milestones, she acknowledged one of her biggest obstacles to be achieving acceptance in the male professional world.

In 2004 and nearing retirement, Betty Hay would go on to say, I am very glad to see in my lifetime the emergence of significantly more career women in science, in an interview with editor-in-chief Fiona Watt for the Journal of Cell Science, this so enriches the intellectual power being applied to the field of cell biology.

Visit link:
Meet Betty Hay, the scientist who saw how cells grow and limbs regenerate - Massive Science

To Read More: Meet Betty Hay, the scientist who saw how cells grow and limbs regenerate – Massive Science
categoriaSkin Stem Cells commentoComments Off on Meet Betty Hay, the scientist who saw how cells grow and limbs regenerate – Massive Science | dataApril 6th, 2020
Read All

Half frog, half machine: The rise of the xenobot – The New Daily

By daniellenierenberg

Just when you thought the world couldnt get any spookier, say hello to the newly born xenobot, a new kind of living thing.

Its hard to say with certainty who the father is.

Or maybe its just hard to admit whats actually happened: Like a bright child making a weirdo companion from Play-Doh, artificial intelligence has mated with the living cells of a frog to create an eerie hybrid of life and machine.

In a statement from the University of Vermont (UVM), the researchers explain it this way: A team of scientists has repurposed living cells, scraped from frog embryos, and assembled them into entirely new life forms.

These millimetre-wide xenobots can live for weeks, travel about with intent, work in groups autonomously, and heal themselves after being cut.

The idea is they could be set sail in their billions to clean the oceans of microplastics.

The really smart ones could be stationed in your organs, where theyd carry out renovating surgery or deliver drugs.

These are novel living machines, says Professor Joshua Bongard, a computer scientist and robotics expert at the University of Vermont who co-led the research.

Theyre neither a traditional robot, nor a known species of animal. Its a new class of artefact: A living, programmable organism.

The new creatures were designed on the Deep Green supercomputer at UVM and then assembled and tested by biologists at Tufts University.

The Deep Green supercomputer cluster at UVMs Vermont Advanced Computing Core used an evolutionary algorithm to create thousands of candidate designs for the new life forms.

Essentially, the computer was told here are your buildings blocks, literally abstract cubes with the physical parameters and limitations of skin and heart cells of an African frog.

The computer was then given an assignment: Arrange the cells so they could move forward. Or side to side. Or herd tiny sheep (no kidding).

And this is where the Play-Doh analogy comes in: The computer would, over and over, reassemble a few hundred simulated cells into myriad forms and body shapes. Is this one OK? What about this one?

Following the same pattern as human beings leaving behind its long-dead ancestors, Homo Erectus and the other hominins that followed, some of the creatures were selected to survive, but the less-successful species went extinct and were tossed to oblivion.

Eventually, the most promising designs were selected for testing.

And this is where it gets spooky.

Because the next step was to bring those building blocks, those red and green cubes, to life.

Here the research shifted from the UVM supercomputer to the biology labs at Tufts University, where stem cells were harvested from the embryos of African frogs, the species Xenopus laevis. (from which the name xenobot is derived).

The cells were separated into single cells and left to incubate.

The creepy yet wondrous thing is, not kept apart, the cells clump together and try to make something of themselves.

Next step: A microsurgeon, Dr Douglas Blackiston, used tiny forceps and an even tinier electrode, to cut the cells and join them under a microscope into a close approximation of the designs specified by the computer.

Assembled into body forms never seen in nature, the cells began to work together, the researchers advise.

The skin cells formed a more passive architecture, while the once-random contractions of heart muscle cells were put to work creating ordered forward motion as guided by the computers design, and aided by spontaneous self-organising patterns allowing the robots to move on their own.

These reconfigurable organisms were shown to be able move in a coherent fashion and explore their watery environment for days or weeks, powered by embryonic energy stores.

Turned over, however, they failed, like beetles flipped on their backs.

Later tests showed that groups of xenobots would work together like cowboys, moving around in circles, pushing pellets into a central location.

They did this spontaneously and collectively. Others were built with a hole through the centre to reduce drag.

In simulated versions, the scientists were able to repurpose this hole as a pouch to successfully carry an object.

We can imagine many useful applications of these living robots that other machines cant do, said co-leader Professor Michael Levin who directs the Centre for Regenerative and Developmental Biology at Tufts, like searching out nasty compounds or radioactive contamination, gathering microplastic in the oceans, travelling in arteries to scrape out plaque.

That fear is not unreasonable, Dr Levin said. When we start to mess around with complex systems that we dont understand, were going to get unintended consequences.

How might the creatures eventually work together in bigger systems?

As the researchers admit, who the heck knows?

A lot of complex systems, like an ant colony, begin with a simple unit an ant from which it would be impossible to predict the shape of their colony or how they can build bridges over water with their interlinked bodies.

Dr Levin said its an absolute necessity for society going forward to get a better handle on systems where the outcome is very complex.

A first step towards doing that is to explore: How do living systems decide what an overall behaviour should be and how do we manipulate the pieces to get the behaviours we want?

In other words, he suggested: This study is a direct contribution to getting a handle on what people are afraid of, which is unintended consequences.

If this was a horror movie, it would go like this: The world is under siege from a malevolent virus.

The frightened populace can think of nothing else.

Meanwhile, creepy monsters made from frog skin decide to take over the joint

More here:
Half frog, half machine: The rise of the xenobot - The New Daily

To Read More: Half frog, half machine: The rise of the xenobot – The New Daily
categoriaSkin Stem Cells commentoComments Off on Half frog, half machine: The rise of the xenobot – The New Daily | dataApril 6th, 2020
Read All

Stem Cell Therapy for Colon Cancer – The Ritz Herald

By daniellenierenberg

An article published in Experimental Biology and Medicine(Volume 245, Issue 6, March 2020)examines the safety of stem cell therapy for the treatment of colon cancer.The study, led by Dr. J. Liu in the State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design at the East China University of Science and Technology in Shanghai (China), reports that mesenchymal stem cells from a variety of sources promote the growth and metastasis of colon cancer cells in an animal model.

Mesenchymal stem (MSCs), a category of adult stem cells, are being evaluated as a therapy for numerous cancers.MSCs are excellent carriers for tumor treatment because they migrate to tumor tissues, can be genetically modified to secrete anticancer molecules and do not elicit immune responses.Clinical trials have shown that MSCs carrying modified genes can be used to treat colon cancer as well as ulcerative colitis. However, some studies have demonstrated MSCs can differentiate into cancer-associated fibroblasts and promote tumor growth.Therefore, additional studies are needed to evaluate the safety of MSCs for targeted treatment of colon cancer.

In the current study, Dr. Liu and colleagues examined the effects of mesenchymal stem cells (MSCs) from three sources (bone marrow, adipose, and placenta) on colon cancer cells.MSCs from all three sources promoted tumor growth and metastasis in vivo. In vitro studies demonstrated that MSCs promote colon cancer cell stemness and epithelial to mesenchymal transition, which would enhance tumor growth and metastasis respectively.Finally, the detrimental effects of MSCs could be reversed by blocking IL-8 signaling pathways. Dr. Ma, a co-author of the study, said that Mesenchymal stem cells have a dual role: promoting and/or suppressing cancer. Which effect is dominant depends on the type of tumor cell, the tissue source of the MSC and the interaction between the MSC and the cancer cell. This is the major issue in the clinical application research of MSCs, and additional preclinical experimental data will be needed to evaluate the safety of MSCs for colon cancer treatment.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine, said: Lui and colleagues have performed elegant studies on the impact of mesenchymal stem cells (MSCs), from various sources, upon the proliferation, stemness, and metastasis of colon cancer stem cells (CSCs) in vitro and in vivo. They further demonstrate that IL-8 stimulates the interaction between colon CSCs and MSCs, and activates the MAPK signaling pathway in colon CSCs.This provides a basis for the further study of MSCs as a biologic therapy for colon cancer.

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership, visit sebm.org.

See the original post:
Stem Cell Therapy for Colon Cancer - The Ritz Herald

To Read More: Stem Cell Therapy for Colon Cancer – The Ritz Herald
categoriaBone Marrow Stem Cells commentoComments Off on Stem Cell Therapy for Colon Cancer – The Ritz Herald | dataApril 6th, 2020
Read All

First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency…

By daniellenierenberg

DetailsCategory: AntibodiesPublished on Monday, 06 April 2020 18:54Hits: 142

Fifteen (15) severely ill COVID-19 patients have been treated under an EIND;

7-day results from the first four patients are available and are very promising;

7-day results for the first 10 patients will be available this week

VANCOUVER, Canada I April 06, 2020 I CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the first two COVID-19 patients have been treated with leronlimab under the Companys Phase 2 randomized clinical trial, which is for patients with mild-to-moderate indications. The Company anticipates that enrollment of more patients will accelerate this week at multiple clinical sites.

In addition, the Companys investigational new drug, leronlimab, has now been administered to 15 severely ill COVID-19 patients atfour hospitals, 10 patients treated at a leading medical center in the New York City area and five patients at three other hospitals, all under an emergency investigational new drug (EIND), which were granted by the U.S. Food and Drug Administration (FDA) for each individual patient.

CytoDyn also anticipates initiating its other COVID-19 trial this week. This trial is a Phase 2b/3 for severely ill COVID-19 patients and is for 342 patients, double-blinded with a 2:1 ratio (drug to placebo ratio). Patients enrolled in this trial are expected to be administered leronlimab for two weeks, with the primary endpoint being the mortality rate at 14 days. The Company will perform an interim analysis on the data from 50 patients following two weeks of leronlimab therapy.

Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, commented, We are encouraged by the positive results demonstrated with leronlimab in the New York patients. Our team is working hard to distribute leronlimab to multiple clinical sites to initiate therapy in patients with severe COVID-19 disease. While every patient is experiencing different comorbidities, we are seeing similar clinical responses, which we believe is a reflection of leronlimabs mechanism of action.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, said, Our partnership with the New York medical team and now other hospitals has been exemplary. We are collaborating in every aspect to deliver leronlimab to patients in order to provide proof of concept as soon as possible. The outstanding coordination among the physicians, the hospital administrators, the FDA, and our team, will hopefully help mitigate the deleterious effects from this pandemic should we prove leronlimab as a solution. The lead physician in New York is a true medical hero, who deserves to be recognized for his contribution to humanity in the pandemic of COVID-19. We are very hopeful of sending the day three and day seven results of the first ten EIND patients to the FDA by the end of this week.

About Coronavirus Disease 2019SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH.Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells.The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in April of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

SOURCE: Cytodyn

Read the original here:
First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency...

To Read More: First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency…
categoriaBone Marrow Stem Cells commentoComments Off on First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency… | dataApril 6th, 2020
Read All

BioIVT Opens New Blood Donor Center to Support Boston-area Research into COVID-19 Therapies, Vaccines and Diagnostics – Yahoo Finance

By daniellenierenberg

Located on the Tufts University Medford, MA campus, this new donor center will enable delivery of fresh blood, leukopaks and buffy coats for COVID-19, cell and gene therapy research within hours of collection

WESTBURY, N.Y., April 6, 2020 /PRNewswire/ --BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the opening of its new blood donor center on the Tufts University campus in Medford, MA to support academic and pharmaceutical researchers involved in COVID-19, cell and gene therapy research.

"BioIVT wants to play a leading role in supporting COVID-19 research efforts and blood donations are a vital resource for the research and development of new therapies, vaccines, and diagnostics. We have many years' experience developing blood products, including blood-derived immune cells for cell and gene therapy research, and we want to make that expertise count," said BioIVT CEO Jeff Gatz. "Researchers recognize and appreciate BioIVT's rapid response and commitment to high quality, fresh blood products and this new donor center will allow us to offer those attributes and services to additional US clients."

BioIVT's new Boston blood donor center is its seventh. The company has similar facilities located in California, Tennessee and Pennsylvania to serve US clients and in London, UK for EU-based clients.

"While the initial focus at our Boston donor center will be on delivering fresh blood, leukopaks and buffy coats within hours of collection, we plan to add more capabilities and donors over time," said Jeff Widdoss, Vice President of Donor Center Operations at BioIVT.

Leukopaks, which contain concentrated white blood cells, are used to help identify promising new drug candidates, assess toxicity levels, and conduct stem cell and gene therapy research. They are particularly useful for researchers who need to obtain large numbers of leukocytes from a single donor.

BioIVT blood products can be supplied with specific clinical data, such as the donor age, ethnicity, gender, BMI and smoking status. Its leukopaks are also human leukocyte antigen (HLA), FC receptor and cytomegalovirus typed. HLA typing is used to match patients and donors for bone marrow or cord blood transplants. FC receptors play an important role in antibody-dependent immune responses.

COVID-19-related Precautions Blood donor centers are considered essential businesses and will remain open during the COVID-19 quarantine. BioIVT is taking additional safety measures to protect both blood donors and its staff during this difficult time. It has instituted several social distancing measures, including increasing the space between chairs in the waiting room and between donor beds, and limiting the entrance of non-essential personnel. The screening rooms are disinfected between donors and all areas of the center continue to be cleaned at regular intervals.

As soon as each blood donor signs their informed consent form, their temperature is taken. If they have a fever, their appointment is postponed, and they are referred to their physician. Any donor who develops COVID-19 symptoms after donating blood is required to inform the center immediately.

All BioIVT blood collections are conducted under institutional review board (IRB) oversight and according to US Food and Drug Administration (FDA) regulations and American Association of Blood Banks (AABB) guidelines.

Those who would like to donate blood at BioIVT's new Boston-area donor center should call 1-833-GO-4-CURE or visit http://www.biospecialty.com to make an appointment.

Further information about the products available from BioIVT's new donor center can be found at https://info.bioivt.com/ma-donor-ctr-req.

About BioIVTBioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit http://www.bioivt.com or follow the company on Twitter @BioIVT.

Story continues

Read more:
BioIVT Opens New Blood Donor Center to Support Boston-area Research into COVID-19 Therapies, Vaccines and Diagnostics - Yahoo Finance

To Read More: BioIVT Opens New Blood Donor Center to Support Boston-area Research into COVID-19 Therapies, Vaccines and Diagnostics – Yahoo Finance
categoriaBone Marrow Stem Cells commentoComments Off on BioIVT Opens New Blood Donor Center to Support Boston-area Research into COVID-19 Therapies, Vaccines and Diagnostics – Yahoo Finance | dataApril 6th, 2020
Read All

FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL AND AGREES TO PRIORITY REVIEW – GlobeNewswire

By daniellenierenberg

NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has accepted for priority review the Companys Biologics License Application (BLA) filing for RYONCILTM (remestemcel-L), its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2020, and if approved, Mesoblast will make RYONCIL immediately available in the United States.

A Priority Review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. The FDA has advised that they are planning to hold an Advisory Committee Meeting to discuss this application.

Mesoblast Chief Executive Dr Silviu Itescu stated: There is a critical need to improve survival outcomes in children suffering from the more advanced stages of this devastating disease. The acceptance of the BLA represents an important milestone for the Company. Mesoblast is on track in its preparation for the potential launch of RYONCIL, including meeting its target inventory build and commercial team roll-out.

About Acute GVHD Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT annually, primarily during treatment for blood cancers, and these numbers are increasing.1 In patients with the most severe form of acute GVHD (Grade C/D or III/IV) mortality is as high as 90% despite optimal institutional standard of care.2,3. There are currently no FDA-approved treatments in the US for children under 12 with SR-aGVHD.

About RYONCILTM Mesoblasts lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising culture- expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in SR- aGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

References

About Mesoblast Mesoblast Limited(Nasdaq: MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblasts proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has filed a Biologics License Application to theUnited States Food and Drug Administration(FDA) to seek approval of its product candidate RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GvHD). Remestemcel-L is also being developed for other rare diseases. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. If approved, RYONCIL is expected to be launched inthe United Statesin 2020 for pediatric steroid-refractory acute GVHD. Two products have been commercialized inJapanandEuropeby Mesoblasts licensees, and the Company has established commercial partnerships inEuropeandChinafor certain Phase 3 assets.

Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as it develops its product candidates for these conditions.

Mesoblast has locations inAustralia,the United StatesandSingaporeand is listed on theAustralian Securities Exchange(MSB) and on the Nasdaq (MESO). For more information, please seewww.mesoblast.com, LinkedIn:Mesoblast Limitedand Twitter: @Mesoblast

Forward-Looking Statements This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward- looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblasts preclinical and clinical studies; Mesoblasts ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblasts product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblasts actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact: Julie Meldrum Corporate Communications T: +61 3 9639 6036 E: julie.meldrum@mesoblast.com

Schond Greenway Investor RelationsT: +1 212 880 2060E: schond.greenway@mesoblast.com

Read this article:
FDA ACCEPTS MESOBLAST'S BIOLOGICS LICENCE APPLICATION FOR RYONCIL AND AGREES TO PRIORITY REVIEW - GlobeNewswire

To Read More: FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL AND AGREES TO PRIORITY REVIEW – GlobeNewswire
categoriaBone Marrow Stem Cells commentoComments Off on FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL AND AGREES TO PRIORITY REVIEW – GlobeNewswire | dataApril 6th, 2020
Read All

Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) – Publicist360

By daniellenierenberg

Global Stem Cell Reconstructive Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 24.5% during a forecast period.

Global Stem Cell Reconstructive Market

Market Dynamics

The Research Report gives an in-depth account of the drivers and restraints in the stem cell reconstructive market. Stem cell reconstructive surgery includes the treatment of injured or dented part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. Growing reconstructive surgeries led by the rising number of limbs elimination and implants and accidents are boosting the growth in the stem cell reconstructive market. Additionally, rising number of aged population, number of patients suffering from chronic diseases, and unceasing development in the technology, these are factors which promoting the growth of the stem cell reconstructive market. Stem cell reconstructive is a procedure containing the use of a patients own adipose tissue to rise the fat volume in the area of reconstruction and therefore helping 3Dimentional reconstruction in patients who have experienced a trauma or in a post-surgical event such as a mastectomy or lumpectomy, brain surgery, or reconstructive surgery as a result of an accident or injury. Stem cell reconstructive surgeries are also used in plastic or cosmetic surgeries as well. Stem cell and regenerative therapies gives many opportunities for development in the practice of medicine and the possibility of an array of novel treatment options for patients experiencing a variety of symptoms and conditions. Stem cell therapy, also recognised as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

The common guarantee of all the undifferentiated embryonic stem cells (ESCs), foetal, amniotic, UCB, and adult stem cell types is their indefinite self-renewal capacity and high multilineage differentiation potential that confer them a primitive and dynamic role throughout the developmental process and the lifespan in adult mammal.However, the high expenditure of stem cell reconstructive surgeries and strict regulatory approvals are restraining the market growth.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/54666

Global Stem Cell Reconstructive Market Segment analysis

Based on Cell Type, the embryonic stem cells segment is expected to grow at a CAGR of XX% during the forecast period. Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their capability to distinguish into any embryonic cell type and by their ability to self-renew. Owing to their plasticity and potentially limitless capacity for self-renewal, embryonic stem cell therapies have been suggested for regenerative medicine and tissue replacement after injury or disease. Additionally, their potential in regenerative medicine, embryonic stem cells provide a possible another source of tissue/organs which serves as a possible solution to the donor shortage dilemma. Researchers have differentiated ESCs into dopamine-producing cells with the hope that these neurons could be used in the treatment of Parkinsons disease. Upsurge occurrence of cardiac and malignant diseases is promoting the segment growth. Rapid developments in this vertical contain protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of several disease models, and evaluation of therapeutic potential in treating incurable diseases.

Global Stem Cell Reconstructive Market Regional analysis

The North American region has dominated the market with US$ XX Mn. America accounts for the largest and fastest-growing market of stem cell reconstructive because of the huge patient population and well-built healthcare sector. Americas stem cell reconstructive market is segmented into two major regions such as North America and South America. More than 80% of the market is shared by North America due to the presence of the US and Canada.

Europe accounts for the second-largest market which is followed by the Asia Pacific. Germany and UK account for the major share in the European market due to government support for research and development, well-developed technology and high healthcare expenditure have fuelled the growth of the market. This growing occurrence of cancer and diabetes in America is the main boosting factor for the growth of this market.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Reconstructive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Reconstructive Market dynamics, structure by analysing the market segments and projects the Global Stem Cell Reconstructive Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Stem Cell Reconstructive Market make the report investors guide.Scope of the Global Stem Cell Reconstructive Market

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/54666

Global Stem Cell Reconstructive Market, By Sources

Allogeneic Autologouso Bone Marrowo Adipose Tissueo Blood Syngeneic OtherGlobal Stem Cell Reconstructive Market, By Cell Type

Embryonic Stem Cell Adult Stem CellGlobal Stem Cell Reconstructive Market, By Application

Cancer Diabetes Traumatic Skin Defect Severe Burn OtherGlobal Stem Cell Reconstructive Market, By End-User

Hospitals Research Institute OthersGlobal Stem Cell Reconstructive Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Stem Cell Reconstructive Market

Osiris Therapeutics NuVasives Cytori Therapeutics Takeda (TiGenix) Cynata Celyad Medi-post Anterogen Molmed Baxter Eleveflow Mesoblast Ltd. Micronit Microfluidics TAKARA BIO INC. Tigenix Capricor Therapeutics Astellas Pharma US, Inc. Pfizer Inc. STEMCELL Technologies Inc.

MAJOR TOC OF THE REPORT

Chapter One: Stem Cell Reconstructive Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Stem Cell Reconstructive Market Competition, by Players

Chapter Four: Global Stem Cell Reconstructive Market Size by Regions

Chapter Five: North America Stem Cell Reconstructive Revenue by Countries

Chapter Six: Europe Stem Cell Reconstructive Revenue by Countries

Chapter Seven: Asia-Pacific Stem Cell Reconstructive Revenue by Countries

Chapter Eight: South America Stem Cell Reconstructive Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Stem Cell Reconstructive by Countries

Chapter Ten: Global Stem Cell Reconstructive Market Segment by Type

Chapter Eleven: Global Stem Cell Reconstructive Market Segment by Application

Chapter Twelve: Global Stem Cell Reconstructive Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Stem Cell Reconstructive Market Report at: https://www.maximizemarketresearch.com/market-report/global-stem-cell-reconstructive-market/54666/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

See original here:
Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Publicist360

To Read More: Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) – Publicist360
categoriaCardiac Stem Cells commentoComments Off on Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) – Publicist360 | dataApril 6th, 2020
Read All

Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa | More News | News Channels -…

By daniellenierenberg

DetailsCategory: More NewsPublished on Thursday, 02 April 2020 14:06Hits: 400

HAMBURG, Germany, and TORONTO, Canada I April 02, 2020 I Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered into a licensing and investment agreement.

Under the terms of the agreement, Evotec will receive a non-exclusive licence to access panCELLas proprietary iPS cell lines iACT Stealth Cells, which are genetically modified to prevent immune rejection of derived cell therapy products (cloaking). Furthermore, Evotec will also have access to a new-generation cloaking technology known as hypoimmunogenic cells. In addition, the FailSafe mechanism effectively addresses a key challenge in iPSC-based cell therapy, potential tumour formation by residual undifferentiated cells.

Using the cell lines, Evotec will be able to develop iPSC-based, off-the-shelf cell therapies with long-lasting efficacy that can be safely administered to a broad population of patients without the use of medication to supress the patients immune system. With a growing portfolio of iPSC-based cell therapy projects at Evotec, access to research as well as GMP-grade iPSC lines modified with one or both of the panCELLa technologies significantly accelerates Evotecs cell therapy discovery and development efforts. Modified iPSC lines will be available for the development of cell therapy approaches across a broad range of indications by Evotec and potential partners. Furthermore, Evotec has made an investment to take a minority stake in panCELLa and has nominated Dr Andreas Scheel to join panCELLas supervisory board.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: Cell therapies hold enormous potential as truly regenerative or curative approaches for a broad range of different diseases with significant medical need. Integrating panCELLas technology and cell lines into our ongoing proprietary research and development efforts strengthens Evotecs position in cell therapy. It is our goal to provide safe highly-effective cell therapy products to as many patients as possible. In addition to small molecules and biologics, cell therapy will become yet another major pillar of Evotecs multimodality discovery and development platform.

Mahendra Rao, MD, PhD, CEO at panCELLa, added: We welcome the partnership with Evotec. Evotecs widely recognised expertise and existing portfolio of iPSC-related technology platforms will allow panCELLa to rapidly advance its own therapeutic interests in NK cell therapy, pancreatic islet production and iPSC-derived MSC platform, in addition to enabling panCELLa to make its platform technologies widely available. I believe that the investment by Evotec in our company is a strong validation of the leading role of panCELLa in the field of regenerative medicine and in the utility of its platform technologies. We welcome Dr Andreas Scheel to our Board.

No financial details of the agreement were disclosed.

About Evotec and iPSC

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanakas lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon for the discovery that mature cells can be reprogrammed to become pluripotent. Pluripotent stem cells hold great promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotecs iPSC platform has been developed over the last years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards, and to use iPSC-based cells in cell therapy approaches via the Companys proprietary EVOcells platform.

About cell therapy and panCELLas FailSafe iPSC technology

Cell therapy, one of the most promising regenerative medicine approaches, replaces a patients missing or broken cells with functioning cells from a range of different sources, either from a donor, from the patients own material, or from stem cells. The advent of induced pluripotent stem cells (iPSC) has opened up stem cells as an almost unlimited source of consistent-quality material for such cell therapies. At the same time, differentiating cell therapies from a single validated source circumvents critical risks of contamination associated with administering both donor and patient cell material.

However, the patients immune system will treat such iPSC-based transplants as foreign and use the bodys immune system to counteract the therapy, thus undermining its long-term efficacy. While organ transplants require an often lifelong regimen of immunosuppressants, iPSC-derived cells used for cell therapies can be cloaked to make them undetectable by the patients immune system, thus avoiding rejection and enabling effective long-term relief of the patients symptoms.

To increase the safety of such iPSC-derived cell products, panCELLas proprietary FailSafe technology is able to inactivate any iPSC-derived proliferating cell before and after transplantation through the use of a readily available anti-infective medication. FailSafe is the only quantifiable safety switch on the market which is expected to be critical for regulators, clinicians and patients to make informed decisions when evaluating treatment options.

ABOUT PANCELLA INC.

Incorporated in August 2015, panCELLa (www.pancella.com) was founded by Dr Andras Nagy and Dr Armand Keating based on Dr Nagys ground-breaking work in the area of stem cell research. Through panCELLa, Drs Keating and Nagy are seeking to create an effective cell therapy derived from stem cells, which are modified to provide a sufficient and very high level of safety before and after the cells are introduced to the patient. panCELLa serves those companies developing products from stem cells. panCELLa seeks to create universal off the shelf FailSafe Cells and to assist pharmaceutical and biotechnology sectors to achieve such with their own cell lines. Targeted medical applications include deadly, debilitating, or aggressive diseases requiring immediate treatment where there is no time to cultivate a customized stem cell treatment from the patient (i.e. cancer, cardiac infarct, diabetes, stroke and spinal cord injury).

SOURCE: Evotec

Continue reading here:
Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa | More News | News Channels -...

To Read More: Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa | More News | News Channels -…
categoriaIPS Cell Therapy commentoComments Off on Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa | More News | News Channels -… | dataApril 6th, 2020
Read All

Evotec partners with panCELLa to enhance cell therapy plaform – ITResearchBrief.com

By daniellenierenberg

Evotec SE- a Germany based biotechnology firm has reportedly signed a licensing and investment agreement with panCELLa Inc. a Canadian innovative biotechnology company.

Reportedly, as per the deal, Evotec is expected to receive a non-exclusive license to use panCELLas patented iPS cell lines known as- iACT Stealth Cells that is genetically enhanced to stop immune rejection of derived cell therapy products. Evotec has also invested in panCELLa to own a minority stake in the company, appointing a member to its supervisory board as well.

In addition to the above, the German biotech giant will also be able to access hypoimmunogenic cells, a next generation cloaking technology. The FailSafe solution meets the challenge in iPSC based cell therapy, which is the probable formation of tumors by remaining undifferentiated cells.

Apparently, with the help of the cell lines, Evotec will gain the ability to develop iPSC-based cell therapies that have long term effectiveness and may be safely administered to a wide base of patients without the use of medicines to need to suppress their immune system.

Notably, with an increase in the number of iPSC- based cell therapy technologies at Evotec, access to research and GMP-grade iPSC lines altered with one or both of the technologies offered by PanCELLa will be available to facilitate the development of novel cell therapy approaches across a wide range of indications by the German company and its potential partners.

In a statement by Dr Cord Dohrmann, Chief Scientific Officer, Evotec, cell therapies carry the potential to cure a wide range of different diseases with considerable unmet medical needs. Integrating the advanced technology of PanCELLa and cell lines into the current research and development will boost Evotecs cell therapy offerings. The company primarily aims at rendering safe and reliable cell therapy solutions to a large number of patients, he further added.

According to Mahendra Rao, MD, PhD and panCELLa CEO, Evotecs product expertise and current range of iPSC-based technology will permit panCELLa to advance its own therapeutic interest in NK cell therapy, iPSC-derived MSC platform and pancreatic islet production at a faster rate along with allowing the company to make its technology widely available.

Source Credits: https://www.evotec.com/en/invest/news--announcements/p/evotec-expands-its-ipsc-based-cell-therapy-platform-evocells-through-licensing-agreement-with-pancella-5921

Read the rest here:
Evotec partners with panCELLa to enhance cell therapy plaform - ITResearchBrief.com

To Read More: Evotec partners with panCELLa to enhance cell therapy plaform – ITResearchBrief.com
categoriaIPS Cell Therapy commentoComments Off on Evotec partners with panCELLa to enhance cell therapy plaform – ITResearchBrief.com | dataApril 6th, 2020
Read All

Cel MD Biotin Shampoo and Conditioner Review – Explosion

By daniellenierenberg

There are plenty of hair products out there that promise all kinds of miraculous results. If youre experiencing hair loss, hair thinning, or damaged hair, you might be at your wits end trying products to bring your hair back to health. With so many different options out there, its hard to know which product to choose. And how can you be sure whether any of them really work?

One of the latest big trends in the beauty industry is the use of natural plant stem cells to help replenish your hair and promote healthy growth. Companies claim that stem cell shampoo could be the answer to all your hair problems. We decided to test out the latest product from Cel MD, the Biotin shampoo and conditioner, and see the results it produced.

What is Cel MD?

Cel MD is a cosmetics company that utilizes patented techniques and cutting-edge science. Its aim is to bring the best in beauty treatments to retail. The company offers lots of different products, most of which use plant stem cells. These and other natural extracts help promote healthy skin and hair.

Stem cells are non-specialized cells that are found in our bodies. They can form any cell, meaning they have great potential for regenerating lost cells, particularly in our hair and skin. Stem cell products like shampoos use plant stem cells and extracts, which can help the body produce more stem cells naturally. This can, in turn, lead to healthier hair.

Biotin Shampoo and Conditioner Ingredients

Cel MDs Biotin shampoo and conditioner include the following active ingredients:

Biotin Stem Cell Shampoo and Conditioner Results

Biotin Stem cell Shampoo and conditioner are most effective for thin and flat hair. These products are supposed to promote new hair growth while also strengthening hair and preventing breakages and damage.

The shampoo is listed as being hypoallergenic, meaning its unlikely to cause any rashes or discomfort. I used the Biotin shampoo and conditioner for six weeks, during which time we followed the instructions provided. Both the shampoo and conditioner were used together, with a short, cold water rinse in between.

After just two weeks of using the product, I found that my hair was softer and looking healthier. I was able to grow my hair longer without suffering from the damaged look that had always happened previously. At the end of the six weeks, my hair was noticeably looking a lot thicker, shinier, and was softer to the touch. My hairstylist commented on how it had improved, and it was clear that the shampoo and conditioner were working their magic.

Originally posted here:
Cel MD Biotin Shampoo and Conditioner Review - Explosion

To Read More: Cel MD Biotin Shampoo and Conditioner Review – Explosion
categoriaSkin Stem Cells commentoComments Off on Cel MD Biotin Shampoo and Conditioner Review – Explosion | dataApril 3rd, 2020
Read All

Page 20«..10..19202122..3040..»